Page 25 - Jon Patton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference News provided by Share this article SAN DIEGO and CALGARY, AB, May 13, 2021 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference, which is taking place virtually from May 18-20, 2021. Presentation details are listed below. Presenter: Dr. Matt Coffey, President & Chief Executive Officer of Oncolytics Biotech Inc. Date: W...

by Jon Ralph Premium Content Subscriber only Alastair Clarkson has been many things across 376 games and 16 seasons, but he has never been boring. Not while he was punching MCG coaches box walls. Or running half-naked around Manuka Oval before the snow fell. Or threatening all manner of deeds as he advised Matthew Lloyd to retire past-match in 2009. Or being saved from a VFL coaching stint by Sam Mitchell's tackle on Shane Tuck. For the first time in forever, Clarkson is coaching a nondescript, vanilla, utterly boring football team. He knows it, and s...

by Jon Ralph Premium Content Subscriber only Alastair Clarkson has been many things across 376 games and 16 seasons, but he has never been boring. Not while he was punching MCG coaches box walls. Or running half-naked around Manuka Oval before the snow fell. Or threatening all manner of deeds as he advised Matthew Lloyd to retire past-match in 2009. Or being saved from a VFL coaching stint by Sam Mitchell's tackle on Shane Tuck. For the first time in forever, Clarkson is coaching a nondescript, vanilla, utterly boring football team. He knows it, and s...

Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results News provided by Share this article Share this article - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareorep's synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors - Phase 2 BRACELET-1 clinical trial on track for...

Oncolytics Biotech Reports 2021 First Quarter Development Highlights and Financial Results - AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize with checkpoint inhibitors - Preclinical studies show that pelareorep's synergistic benefits extend across multiple classes of immunotherapeutic agents, including novel CAR T approaches in solid tumors - Phase 2 BRACELET-1 clinical trial on track for full enrollment in Q4-2021 - Strong financial foundation...